Korean Journal of Food Science and Technology (한국식품과학회지)

Korean Society of Food Science and Technology (한국식품과학회)
권호 표지

Evaluation of the Cytotoxic Effects of Resveratrol Treatment with Over-the-counter Drugs on the Hepatic and Intestinal Cells

식이 폴리페놀 성분 resveratrol과 일반의약품의 복합처리에 의한 간 및 장관계 세포독성 평가

  • Kim, Da-Ram (Division of Food Science, College of Natural Science, Seoul Women's University) ;
  • Kim, Mi-Ri (Division of Food Science, College of Natural Science, Seoul Women's University) ;
  • Hong, Jung-Il (Division of Food Science, College of Natural Science, Seoul Women's University)
  • 김다람 (서울여자대학교 자연과학대학 식품과학부) ;
  • 김미리 (서울여자대학교 자연과학대학 식품과학부) ;
  • 홍정일 (서울여자대학교 자연과학대학 식품과학부)
  • Received : 2009.11.19
  • Accepted : 2010.01.15
  • Published : 2010.04.30
Download PDF
⟨ Previous Next ⟩

Abstract

Resveratrol is a natural polyphenolic compound frequently found in grapes. The biological actions of resveratrol have been extensively investigated both in vitro and in vivo. The interactions of resveratrol with commonly-consumed drugs, however, have rarely been studied. In this study, the cytotoxic properties of resveratrol on the hepatic and intestinal cells in the presence of over-the-counter (OTC) drugs, including acetaminophen (AAP), aspirin (Asp), and ibuprofen (Ibu), were evaluated. The cytotoxic effects of resveratrol on hepatic HepG2 and colonic HCT 116 cells were not markdely changed in the presence of AAP, Asp, or Ibu. Conversely, the cytotoxicity of OTC drugs was not affected by resveratrol either. Concentrations of resveratrol below 10 mM significantly increased HepG2 cell growth after 48 or 72 hr incubation; however, the growth-stimulating effect was not observed in the presence of AAP. When HCT 116 cells were treated with OTC drugs before or after resveratrol, the cytotoxic effects were not significantly altered. The present study provides basic information for the potential health effects of the interactions between resveratrol and commonly-consumed OTC drugs.

본 연구에서는 널리 섭취되는 식이 폴리페놀 화합물인 resveratrol과 일반의약품 성분 AAP, Asp 및 Ibu와의 혼용 시 일어날 수 있는 상호작용에 의한 세포독성 변화를 조사하였다. Resveratrol은 장관계 HCT 116 세포와 간 HepG2 세포에 농도의존적인 세포활성 감소를 초래하였고 각각 113.8 및 $135.7\;{\mu}M$의 $IC_{50}$ 수치를 보였다. 농도별 resveratrol과 AAP, Asp 또는 Ibu를 각 세포에 24시간 복합투여하였을 때 일부 유의적인 resvertrol 독성의 감소나 증가가 나타났지만 전체적으로 10% 이내의 미미한 변화를 보였다. AAP, Asp 및 Ibu의 고농도 처리시 발생하는 세포독성에 대한 resveratrol의 효과를 HepG2 세포와 IEC-6 정상장관계 세포에서 비교하였을 때 현저한 약물 독성의 변화 또한 관찰되지 않았다. HepG2 세포에 저농도의 resveratrol을 48, 72시간 처리하였을 때 유의적인 세포증식 촉진효과가 나타났으나, AAP와 복합투여시 그 효과는 소멸되었다. 한편 일반의약품 성분과 resveratrol을 각각 순서를 달리하여 전후로 세포에 처리하였을 때에도 현저한 독성의 변화는 나타나지 않았다. Resveratrol과 빈번히 복용되는 일반의약품 AAP, Asp, Ibu를 여러 조합에 의해 복합처리하여 세포독성을 평가한 결과, 이들의 상호작용에 의한 두드러진 독성발현 및 활성변화는 발견되지 않았다.

Keywords

References

  1. Jang M, Cai L, Udeani GO, Slowing KV, Thomas CF, Beecher CW, Fong HH, Farnsworth NR, Kinghorn AD, Mehta RG, Moon RC, Pezzuto JM. Cancer chemopreventive activity of resveratrol, a natural product derived from grapes. Science 275: 218-220 (1997) https://doi.org/10.1126/science.275.5297.218
  2. Kopp P. Resveratrol, a phytoestrogen found in red wine. A possible explanation for the conundrum of the 'French paradox?'. Eur. J. Endocrinol. 138: 619-620 (1998) https://doi.org/10.1530/eje.0.1380619
  3. Subbaramaiah K, Chung WJ, Michaluart P, Telang N, Tanabe T, Inoue H, Jang M, Pezzuto JM, Dannenberg AJ. Resveratrol inhibits cyclooxygenase-2 transcription and activity in phorbol ester-treated human mammary epithelial cells. J. Biol. Chem. 273: 21875-21882 (1998) https://doi.org/10.1074/jbc.273.34.21875
  4. Chun YJ, Kim MY, Guengerich FP. Resveratrol is a selective human cytochrome P450 1A1 inhibitor. Biochem. Biophys. Res. Co. 262: 20-24 (1999) https://doi.org/10.1006/bbrc.1999.1152
  5. Holmes-McNary M, Baldwin AS. Chemopreventive properties of transresveratrol are associated with inhibition of activation of the I B kinase. Cancer Res. 60: 3477-3483 (2000)
  6. Bhat-Krishna PL, Pezzuto JM. Resveratrol exhibits cytostatic and antiestrogenic properties with human endometrial adenocarcinoma (Ishikawa) cells. Cancer Res. 61: 6137-6144 (2001)
  7. Gehm BD, Mcandrews JM, Chien P, Jamesonon JL. Resveratrol, a polyphenolic compound found in grapes and wine, is an agonist for the estrogen receptor. Proc. Natl. Acad. Sci. USA 94: 14138-14143 (1997) https://doi.org/10.1073/pnas.94.25.14138
  8. Moreno J. Resveratrol modulates arachidonic acid release prostaglandin synthesis, and 3T6 fibroblast growth. J. Pharmacol. Exp. Ther. 294: 333-338 (2000)
  9. Casper RF, Quesne M, Rogers IM, Shirota T, Jolivel A, Milgrom E, Savouret JF. Resveratrol has antagonistic activity on the aryl hydrocarbon receptor: implications for prevention of dioxin toxicity. Mol. Pharmacol. 56: 784-790 (1999)
  10. Hsieh Tch, Wu JM. Differential effects on growth, cell cycle arrest, and induction of apoptosis by resveratrol in human prostate cancer cell lines. Exp. Cell Res. 249: 109-115 (1999) https://doi.org/10.1006/excr.1999.4471
  11. Mgbonyevi OP, Russo J, Russo LH. Antiproliferative effect of synthetic resveratrol on human breast epithelial cells. Int. J. Oncol. 12: 865-869 (1988)
  12. SzendeB, Tyihak E, Kiraly-Veghely Z. Dose-dependent effect of resveratrol on proliferation and apoptosis in endothelial and tumor cell cultures. Exp. Mol. Med. 32: 88-92 (2000) https://doi.org/10.1038/emm.2000.16
  13. Mitchell JR, Jollow DJ, Potter WZ, Davis DC, Gillette JR, Brodie BB. Acetaminophen-induced hepatic necrosis. I. Role of drug metabolism. J. Pharmacol. Exp. Ther. 187: 185-194 (1973)
  14. Jollow DJ, Mitchell JR, Potter WZ, Davis DC, Gillette JR, Brodie BB. Acetaminophen-induced hepatic necrosis. II. Role of covalant binding in vivo. J. Pharmacol. Exp. Ther. 187: 195-202 (1973)
  15. Ratliff TL. Aspirin, Ibuprofen, and other non-steroidal antiinflammatory drugs in cancer prevention: A critical review of non-selective COX-2 blockade (Review). J. Urology 174: 787-788 (2005)
  16. Bailey DG, Arnold JMO, Bend JR, Tran LT, Spence JD. Grapefruit juice-felodipine interaction: Reproducibility and characterization with the extended release drug formulation. Brit. J. Clin. Pharmacol. 40: 135-140 (1995)
  17. Bailey DG, Spence JD, Munoz C, Arnold JMO. Interaction of citrus juices with felodipine and nifedipine. Lancet 337: 268-269 (1991) https://doi.org/10.1016/0140-6736(91)90872-M
  18. Bailey DG, Spence JD, Edgar B, Bayliff CD, Arnold JMO. Ethanol enhances the hemodynamic effects of felodipine. Clin. Invest. Med. 12: 357-362 (1989)
  19. Bailey DG, Malcolm J, Arnold O, David Spence J. Grapefruit juice-drug interactions. Brit. J. Clin. Pharmacol. 46: 101-110 (1998)
  20. Dahan A, Altman H. Food-drug interaction: grapefruit juice augments drug bioavailability-mechanism, extent and relevance. Eur. J. Clin. Nutr. 58: 1-9 (2004) https://doi.org/10.1038/sj.ejcn.1601736
  21. Teschke R, Stutz G, Strohmeyer G. Increased paracetamol-induced hepatotoxicity after chronic alcohol consumption. Biochem. Biophys. Res. Co. 91: 368-374 (1979) https://doi.org/10.1016/0006-291X(79)90628-4
  22. Sato C, Matsuda Y, Lieber CS. Increased hepatotoxicity of acetaminophen after chronic ethanol consumption in the rat. Gastroenterology 80: 140-148 (1981)
  23. Whitcomb DC, Block GD. Association of acetaminophen hepatotoxicity with fasting and ethanol use. J. Am. Med. Assoc. 272: 1845-1850 (1994) https://doi.org/10.1001/jama.272.23.1845
  24. Sinclair J, Jeffery E, Wrighton S, Kostrubsky V, Szakacs J, Wood S, Sinclair P. Alcohol-mediated increases in acetaminophen hepatotoxicity: Role of CYP2E and CYP3A. Biochem. Pharmacol. 55: 1557-1565 (1998) https://doi.org/10.1016/S0006-2952(97)00656-4